Researchers have developed various delivery routes, including polymeric nanoparticles, gold nanoparticles, targeted adeno-associated virus particles, and natural-protein drug-delivery systems that can target cancer-specific plectin and promote targeted delivery to PC cells.[74, 75, 76, 77, 78] Despite in vivo and in vitro validation of these delivery modalities, these modes of administration are yet to be implemented clinically, warranting further investigations to determine their therapeutic efficacy and safety. The gene discussed is PLEC; the disease is cancer.